Zacks Investment Research lowered shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a sell rating in a research report released on Tuesday.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Several other equities research analysts also recently weighed in on the company. Maxim Group downgraded Capricor Therapeutics from a buy rating to a hold rating in a report on Wednesday, December 26th. HC Wainwright cut their price objective on Capricor Therapeutics from $8.60 to $3.50 and set a buy rating on the stock in a report on Monday, December 31st. TheStreet downgraded Capricor Therapeutics from a c- rating to a d+ rating in a report on Monday, October 15th. Finally, ValuEngine downgraded Capricor Therapeutics from a hold rating to a sell rating in a report on Friday, December 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $3.00.

Shares of NASDAQ CAPR traded down $0.01 during mid-day trading on Tuesday, hitting $0.60. 76,236 shares of the stock traded hands, compared to its average volume of 96,613. Capricor Therapeutics has a twelve month low of $0.31 and a twelve month high of $2.29. The company has a market cap of $18.10 million, a price-to-earnings ratio of -1.36 and a beta of -1.06.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.01). Capricor Therapeutics had a net margin of 24.75% and a negative return on equity of 159.36%. The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.90 million. Equities research analysts anticipate that Capricor Therapeutics will post -0.57 EPS for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

See Also: Trading Penny Stocks

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.